Avera turns the most routine scan in women's medicine into a quantitative cardiovascular signal. The only model that measures breast arterial calcification in absolute mm², across every major scanner.
Across Emory and Mayo Clinic, five sites, three scanner manufacturers — the largest published BAC quantification cohort.
After adjustment for the AHA PREVENT score. Each additional mm² adds roughly 2% to a woman's major adverse cardiac event risk.
Existing commercial models flag presence or absence. Avera measures severity, in absolute mm² — the cardiovascular equivalent of an Agatston score.
Cardiovascular disease is the leading killer of women, and the calcification that warns of it has been sitting, unread, on routine mammograms for thirty years.
Breast arterial calcification is visible on every screening mammogram. But it's reported on almost none. The eye is unreliable; the standard is missing.
Avera outputs an absolute measurement of calcified arterial area in square millimetres — a continuous severity signal that mirrors the coronary Agatston score clinicians already trust.
The model segments calcified arterial pixels across each view, then integrates total area into a single severity number. Output is reproducible, comparable across visits, and built for trend analysis over a woman's screening history.
Validated across Hologic, GE and LORAD systems — the dominant installed base in US imaging centres. The only multi-vendor BAC model in the literature, and the foundation of our advantage over single-vendor incumbents.
Developed at Emory and validated across the Mayo Clinic and three additional sites, the Avera model significantly improves cardiovascular risk discrimination on top of the AHA PREVENT score — a clinically meaningful gain in a population that current tools systematically underserve.
Avera reads the DICOMs you already capture. The cardiovascular signal arrives alongside the radiologist's mammography read — same workflow, same patient, one additional answer.
Standard CC and MLO views, any of the three major scanners. No extra acquisition, no patient prep, no change to the technologist's day.
The model segments calcifications across views, integrates total area, and emits a continuous severity score — comparable across visits and across scanners.
Severity tier and an evidence-anchored note land in the report — ready for the radiologist, the primary-care follow-up, and the cardiology referral when it's warranted.
Because BAC quantification is a continuous measurement on a routine, repeated scan, Avera turns every screening visit into a data point — and a woman's risk into a trajectory rather than a snapshot.
Add cardiovascular intelligence to your screening offering. A differentiated patient experience and a new line item, with no new hardware.
Surface high-risk women earlier in the cardiology funnel. Improve risk capture and downstream outcomes across the female population you already see.
A reproducible, scanner-agnostic BAC score for retrospective cohorts. Build the next decade of women's cardiovascular evidence on a continuous measure.
We're partnering with imaging networks, health systems and women's-health researchers ahead of broader availability. Tell us about your population and we'll come back with a pilot proposal.